DE69932719D1 - Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben - Google Patents

Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben

Info

Publication number
DE69932719D1
DE69932719D1 DE69932719T DE69932719T DE69932719D1 DE 69932719 D1 DE69932719 D1 DE 69932719D1 DE 69932719 T DE69932719 T DE 69932719T DE 69932719 T DE69932719 T DE 69932719T DE 69932719 D1 DE69932719 D1 DE 69932719D1
Authority
DE
Germany
Prior art keywords
verotoxin
humanized antibodies
manufacture
detection
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69932719T
Other languages
English (en)
Other versions
DE69932719T2 (de
Inventor
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Man Sung Co
Maximiliano Vasques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
PDL Biopharma Inc
Original Assignee
Teijin Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Protein Design Labs Inc filed Critical Teijin Ltd
Publication of DE69932719D1 publication Critical patent/DE69932719D1/de
Application granted granted Critical
Publication of DE69932719T2 publication Critical patent/DE69932719T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69932719T 1998-05-20 1999-05-19 Humanisierte Antikörper zur Erkennung von Verotoxin II sowie Zelllinie zur Herstellung derselben Expired - Lifetime DE69932719T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20
US86570P 1998-05-20
PCT/US1999/011179 WO1999059629A1 (en) 1998-05-20 1999-05-19 Humanized antibodies that recognize verotoxin ii and cell line producing same

Publications (2)

Publication Number Publication Date
DE69932719D1 true DE69932719D1 (de) 2006-09-21
DE69932719T2 DE69932719T2 (de) 2007-09-13

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69932719T Expired - Lifetime DE69932719T2 (de) 1998-05-20 1999-05-19 Humanisierte Antikörper zur Erkennung von Verotoxin II sowie Zelllinie zur Herstellung derselben

Country Status (20)

Country Link
US (1) US7846435B1 (de)
EP (1) EP1079856B1 (de)
JP (1) JP4044733B2 (de)
KR (1) KR100548167B1 (de)
CN (1) CN1330375C (de)
AT (1) ATE335504T1 (de)
AU (1) AU748852B2 (de)
BR (1) BR9910589A (de)
CA (1) CA2328485C (de)
DE (1) DE69932719T2 (de)
DK (1) DK1079856T3 (de)
ES (1) ES2270598T3 (de)
HK (1) HK1036215A1 (de)
IL (2) IL139571A0 (de)
NO (1) NO326197B1 (de)
NZ (1) NZ508119A (de)
PT (1) PT1079856E (de)
RU (1) RU2217166C2 (de)
WO (1) WO1999059629A1 (de)
ZA (1) ZA200006370B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
EP2019684A4 (de) 2006-04-20 2009-08-26 Jackson H M Found Military Med Verfahren und zusammensetzungen auf der basis von shigatoxin-typ-1-protein
PE20120425A1 (es) 2009-01-23 2012-05-03 Jackson H M Found Military Med Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
ES2749120T3 (es) * 2013-05-27 2020-03-19 Inmunova S A Quimeras de lumazina sintasa de Brucella y subunidad beta de toxinas AB5
SG11201605691VA (en) * 2014-01-16 2016-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
EP0817647A4 (de) 1995-03-24 2002-10-30 Promega Corp Behandlung von verotoxin-produzierenden escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
JP2002515230A (ja) 2002-05-28
BR9910589A (pt) 2001-01-16
PT1079856E (pt) 2006-12-29
AU748852B2 (en) 2002-06-13
EP1079856A1 (de) 2001-03-07
HK1036215A1 (en) 2001-12-28
CN1330375C (zh) 2007-08-08
ATE335504T1 (de) 2006-09-15
IL139571A0 (en) 2002-02-10
NO20005833D0 (no) 2000-11-17
CN1301175A (zh) 2001-06-27
ZA200006370B (en) 2001-08-22
NZ508119A (en) 2003-06-30
CA2328485C (en) 2011-05-03
JP4044733B2 (ja) 2008-02-06
RU2217166C2 (ru) 2003-11-27
CA2328485A1 (en) 1999-11-25
EP1079856B1 (de) 2006-08-09
AU4090499A (en) 1999-12-06
KR20010052367A (ko) 2001-06-25
IL139571A (en) 2009-09-22
NO20005833L (no) 2001-01-15
EP1079856A4 (de) 2002-03-13
KR100548167B1 (ko) 2006-01-31
NO326197B1 (no) 2008-10-13
WO1999059629A1 (en) 1999-11-25
US7846435B1 (en) 2010-12-07
ES2270598T3 (es) 2007-04-01
DK1079856T3 (da) 2006-12-04
DE69932719T2 (de) 2007-09-13

Similar Documents

Publication Publication Date Title
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
EP1135415A4 (de) Humanisierte antikoerper gegen gamma-interferon
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE266726T1 (de) CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
DE60210413D1 (de) Zusammensetzungen zur immunisierung sowie deren verwendung
DE69939820D1 (de) Internalisierende erbb2 antikörper
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
EP2360169A3 (de) PSMA Antikörper
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
DE69932719D1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
ATE180974T1 (de) Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
WO2005072126A3 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TEIJIN LTD., OSAKA, JP

Owner name: PDL BIOPHARMA, INC., FREMONT, CALIF., US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PDL BIOPHARMA, INC., REDWOOD CITY, CALIF., US

Owner name: TEIJIN LTD., OSAKA, JP